@article{76fde00049d848cf92f7fa6cd6c4460a,
title = "Radiation-agent combinations for glioblastoma: challenges in drug development and future considerations",
abstract = "Glioblastoma is an aggressive disease characterized by moderate initial response rates to first-line radiation–chemotherapy intervention followed by low poor response rates to second-line intervention. This article discusses novel strategic platforms for the development of radiation–investigational agent combination clinical trials for primary and recurrent glioblastoma in a NCI-NCTN settings with simultaneous analysis of challenges in the drug development process.",
keywords = "Cancer discovery, Clinical cancer research, Clinical trials, Experimental chemotherapy, Precision medicine, Radiotherapy",
author = "Kunos, {Charles A.} and Evanthia Galanis and Jeffrey Buchsbaum and Qian Shi and Strauss, {Lewis C.} and Coleman, {C. Norman} and Ahmed, {Mansoor M.}",
note = "Funding Information: Acknowledgements We wish to thank Dr. Amanda J. Walker for critical reading of the manuscript and providing FDA{\textquoteright}s perspective on cancer drug radiation combination. This work was supported by grants from NCI (R01CA154348 and P50 CA10896) award to EG. Funding Information: We wish to thank Dr. Amanda J. Walker for critical reading of the manuscript and providing FDA?s perspective on cancer drug radiation combination. This work was supported by grants from NCI (R01CA154348 and P50 CA10896) award to EG. Authors CAK, EG, JB, QS, LCS, CNC and MMA do not have any conflicts of interest. Publisher Copyright: {\textcopyright} 2017, Springer Science+Business Media New York (outside the USA).",
year = "2017",
month = sep,
day = "1",
doi = "10.1007/s11060-017-2458-0",
language = "English (US)",
volume = "134",
pages = "551--557",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "3",
}